Human reduced folate carrier gene and transcript variants: Functional, physiologic, and pharmacologic consequences

Current Pharmacogenomics

Volumn 2, Issue 3, 2004, Pages 287-298

  Matherly, Larry H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Methotrexate; Polymorphism; Promoter; Reduced folate carrier; Untranslated region

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; ARGININE; CYTOSINE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLIC ACID ANTAGONIST; GLYCINE HYDROXYMETHYLTRANSFERASE; GUANINE; HISTIDINE; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; METHIONINE SYNTHASE; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RALTITREXED; REDUCED FOLATE CARRIER; TETRAHYDROFOLIC ACID; THYMIDYLATE SYNTHASE; THYMINE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BASE PAIRING; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DOWNSTREAM PROCESSING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TRANSPORT; FETUS MALFORMATION; FOLIC ACID DEFICIENCY; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENE INSERTION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; NONHUMAN; OSTEOSARCOMA; PROMOTER REGION; PSORIASIS; REVIEW;

INSERTION SEQUENCES; MAMMALIA;

EID: 4444302761     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570160043377547     Document Type: Review

References (103)

1. Antony, A. C. (1996) Folate receptors. Annu. Rev. Nutr, 16, 501-521
2. Brattstrom, L.; Wilcken, D. E.; Ohrvik, J.; Brudin, L. (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98, 2520-2526
3. Calabresi, P.; Parks, R. E. (1985) Antiproliferative agents and drugs used for immunosuppression. In: The Pharmacological Basis of Therapeutics (Goodman Gilman A, Goodman LS, Rall TW, Murad F, eds) New York: Macmillan Publishing Company, pp. 1247-1306
4. Chango, A.; Emery-Fillon, N.; de Courcy, G. P.; Lambert, D.; Pfister, M.; Rosenblatt, D. S.; Nicolas, J. P. (2000) A polymorphism (80G←A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab. 70, 310-315
5. Chen, L.; Qi, H.; Korneberg, J.; Garrow, T. A.; Choi, Y. -J.; Shane, B. (1996) Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 271, 13077-13087
6. Chen, Z. S.; Lee, K.; Walther, S.; Raftogianis, R. B.; Kuwano, M.; Zeng, H., Kruh, G. D. (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component ofthe methotrexate efflux system. Cancer Res. 62, 3144-3150
7. Chiao, J. H.; Roy, K.; Tolner, B.; Yang, C. H.; Sirotnak, F. M. (1997) RFC-1 gene expression regulates folate absorption in mouse small intestine. J. Biol. Chem. 273, 11165-11170
8. Day, D. A.; Tuite, M. F. (2003) Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J. Endocrinol. 157, 361-371
9. De Marco, P.; Calevo, M. G.; Moroni, A.; Merello, E.; Raso, A.; Finnell, R.H.; Zhu, H.; Andreussi, L.; Cama, A.; Capra, V. (2003) Reduced folate carrier polymorphism (80A←G) and neural tube defects. Eur. J. Hum. Genet. 11, 245-252
10. Drori, S.; Jansen, G.; Mauritz, R.; Peters, G. J.; Assaraf, Y. G. (2000a) Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J. Biol. Chem. 275, 30855-30863
11. Drori, S.; Sprecher, H.; Shemer, G.; Jansen, G.; Goldman, I. D.; Assaraf, Y.G. (2000b). Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur. J. Biochem. 267, 690-702
12. Fiaschi, T.; Chiarugi, P.; Veggi, D.; Raugei, G.; Ramnponi, G. (2000) The inhibitory effect of the 5′ untranslated region of muscle acylphosphatase mRNA on protein expression is relieved during cell differentiation. FEBS Lett. 473, 42-46
13. Flatley, R. M.; Payton, S. G.; Whetstine, J. R.; Taub, J. W.; Matherly, L. H. (2003) Primary acute lymphoblastic leukemia cells use a novel promoter and 5′ non-coding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Proceedings AACR 44, 598
14. Fournier, B.;Trunong-Bolduc, Q. C.; Zhang, X; Hooper, D. C. (2001) A mutation in the 5′ untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J. Bacteriol. 183, 2367-2371
15. Frosst, P.; Blom, H. J.; Milos, R.; Goyette, P.; Sheppard, C. A.; Matthews, R. G.; Boers, G. J.; den Heijer, M.; Kluijtmans, L. A.; van den Heuvel, L. P.; et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahyrofolate reductase [letter]. Nat. Gen. 10,111-113
16. Gifford, A. J.; Haber, M.; Witt, T. L.; Whetstine, J. R.; Taub, J. W.; Matherly, L. H.; Norris, M. D. (2002) Role of the E45K reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia 16, 2379-2387
17. Gifford, A. J.; Whetstine, J. R.; Bark, K. S.; Kulkarni, J. S.; Taub, J. W.; Haber, M.; Norris, M. D.; Matherly, L. H. (2000) Mutations in the reduced folate carrier gene (RFC) in childhood acute lymphoblastic leukemia (ALL). Proceedings, AACR 41, 758
18. Goldman, I. D.; Matherly, L. H. (1985) The cellular pharmacology of methotrexate. Pharmacol. Ther. 28, 77-100
19. Goldman, I. D.; Zhao, R. (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol. 29, 3-17
20. Goldman, I. D. (1971) The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann. NY Acad. Sci. 186, 400-422
21. Gong, M.; Yess, J.; Connolly, T.; Ivy, S. P.; Ohnuma, T.; Cowan, K. H.; Moscow, J. A. (1997) Molecular mechanism of antifolate transport deficienc in a methotrexate resistant MOLT-3 human leukemia cell line. Blood 89, 2494-2499
22. Gorlick, R.; Goker, E.; Trippett, T.; Steinherz, P.; Elisseyeff, Y.; Mazumdar,M.; Flintoff, W. F.; Bertino, J. R. (1997) Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89, 1013-1018
23. Goto, Y.; Yue, L.; Yokoi, A.; Nishimura, R.; Uehara, T.; Koizumi, S.; Saikawa, Y. (2001) A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7, 1952-1956
24. Guo, W.; Healey, J. H.; Meyers, P. A.; Ladanyi, M.; Huvos, A. G.; Bertino, J. R; Gorlick, R. (1999) Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 5, 621-627
25. Haagsma, C. J.; Blom, H. J.; van Riel, P. L.; van't Hof, M. A.; Giesendorf, B. A.; van Oppenraaij-Emmerzaal, D.; van de Putte, L. B. (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58, 79-84
26. Harmon, D. L.; Woodside, J. V.; Yarnell, J. W.; McMaster, D.; Young, I. S.; McCrum, E. E.; Gey, K. F.; Whitehead, A. S.; Evans, A. E. (1996) The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 89, 571-577
27. Heil, S. G.; Van der Put, N. M.; Waas, E. T.; den Heijer, M.; Trijbels, F. J.; Blom, H. J. (2001) Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol. Genet. Metab. 73, 164-172
28. Henderson, G. B.; Zevely, E. M. (1980) Transport of methotrexate in L1210 cells: effect of ions on the rate and extent of uptake. Arch. Biochem. Biophys. 200, 149-155
29. Henderson, G. B.; Zevely, E. M. (1981) Anion exchange mechanism for transport of methotrexate in L1210 cells. Biochem. Biophys. Res. Commun. 99, 163-169
30. Henderson, G. B.; Zevely, E. M. (1983) Structural requirements for anion substrates of the methotrexate transport system of L1210 cells. Arch. Biochem. Biophys. 221, 438-446
31. Henderson, G. B.; Zevely, E. M. (1984)Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J. Biol. Chem. 259, 1526-1531
32. Hirohashi, T.; Suzuki, H.; Sugiyama, Y. (1999). Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 274, 15181-15185
33. Hooijberg, J. H.; Broxterman, H. J.; Kool, M.; Assaraf, Y. G.; Peters, G. J.; Noordhuis, P.; Scheper, R. J.; Borst, P.; Pinedo, H. M.; Jansen, G. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59, 2532-2535
34. Horie, N.; Aiba, H.; Ogurao, K.; Hojo, H.; Takeishi, K. (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197
35. Horne, D. W.; Reed, K. A. (2001)Transport of methotrexate into PC-3 human prostate cancer cells. Arch. Biochem. Biophys. 394, 39-44
36. Jansen, G. (1999) Receptor- and carrier-mediated transport systems for folates and antifolates. Exploitation for folate chemotherapy and immunotherapy. In: Anticancer Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL, ed) Totowa, NJ: Humana Press Inc., 293-321.
37. Jansen, G.; Mauritz, R.; Drori, S.; Sprecher, H.; Kathmann, I.; Bunni, M.; Priest, D. G.; Noordhuis, P.; Schornagel, J. H.; Pinedo, H. M.; Peters, G. J.; Assaraf, Y. G. (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273, 30189-30198
38. Jacques, P. F.; Bostom, A. G.; Williams, R. R.; Ellison, R. C.; Eckfeldt, J. H.; Rosenberg, I. H.; Selhub, J.; Rozen, R. (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7-9
39. Kaneda, S.; Takeishi, K.; Ayusawa, D.; Shimizu, K.; Seno, T.; Altman, D. (1987) Role in trnslation of a triple tandemly repeated sequece in the 5′ untranslated region of the human thymidylate synthase mRNA. Nucleic Acids Res, 15, 1259-1270
40. Kaufman, Y.; Drori, S.; Cole, P. D.; Kamen, B. A.; Sirota, J.; Ifergan, I; Arush, M. W.; Elhasid, R.; Sahar, D.; Kaspers, G. J.; Jansen, G.; Matherly, L. H.; Rechavi, G.; Toren, A.; Assaraf, Y. G. (2004) Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer 100, 773-782.
41. Kawakami, K.; Salonga, D.; Park, J. M.; Danenberg, K. D.; Uetake, H.; Brabender, J.; Omura, K.; Watanabe, G.; Danenberg, P. V. (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7, 4096-4101
42. Kishi, S.; Griener, J.; Cheng, C.; Das, S.; Cook, E. H.; Pei, D.; Hudson, M.; Rubnitz, J.; Sandlund, J. T.; Pui, C. H.; Relling, M. V. (2003) Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 21, 3084-3091
43. Kocarek, T. A.; Zangar, R. C.; Novak, R. F. (2000) Post-transcriptional regulation of rat CYP2E1 expression: role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Arch. Biochem. Biophys. 376, 180-190
44. Kumar, C. K.; Nguyen, T. T.; Gonzales, F. B.; Said, H. M. (1998) Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. Am. J. Physiol. 274, C289-294
45. Kusuhara, H.; Han, Y. H.; Shimoda, M.; Kokue, E.; Suzuki, H.; Sugiyama, Y. (1998) Reduced folate derivatives are endogenous substrates for CMOAT in rats. Am. J. Physiol, 275, G789-G796
46. Laverdiere, C.; Chiasson, S.; Costea, I.; Moghrabi, A.; Krajinovic, M. (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100, 3832-3834
47. Lawrence, J. M.; Petitti, D. B.; Watkins, M.; Umekubo, M. A. (1999) Trends in serum folate after food fortification. Lancet 354, 915-916
48. Leclerc, D.; Campeau, E.; Goyette, P.; Adjalla, C. E.; Christensen, B.; Ross, M.; Eydoux, P.; Rosenblatt, D. S.; Rozen, R.; Gravel, R. A. (1996) Human methionine synthase: cDNA cloning and identification of mutations in patients of the cbIG complementation group of folate/cobalamin disorders. Hum. Mol. Genet. 5, 1867-1874
49. Lenz, H. J.; Zhang, W.; Zhahedy, S.; Gil, J.; Yu, M.; Stroehlmacher, J. (2002) A 6 base-pair deletion in the 3′UTR of the thymidylate synthase (TS) gene predicts thymidylate synthase mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk. Proceedings AACR 43, 660
50. Lucock, M. (2000) Folic acid: Nutritional biochemistry, molecular biology, and role in disease processes. Mol. Genet. Metabol. 71, 121-138
51. Ma, J.; Stampfer, M. J.; Hennekens, C. H.; Frosst, P.; Selhub, J.; Horsford, J.; Malinow, M. R.; Willett, W. C.; Rozen, R. (1996) Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94, 2410-2416
52. Mandola, M. V.; Stoehlmacher, J.; Muller-Weeks, S.; Cesarone, G.; Yu, M. C.; Lenz, H. J.; Ladner, R. D. (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904
53. Marsh, S.; Ameyaw, M. M.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D.; McLeod, H. L. (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16, 528
54. Marsh, S.; McKay, J. A.; Cassidy, J.; McLeod, H. L. (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 29, 383-386
55. Matherly, L. H.; Goldman, I. D. (2003) Membrane transport of folates. Vitamins and Hormones 66, 403-456
56. Matherly, L. H. (2001) Molecular and cellular biology of the human reduced folate carrier. Progress in Nucleic Acid Research and Molecular Biology. 67, 131-161
57. Meisel, C.; Cascorbi, I.; Gerloff, T.; Stangl, V.; Laule, M.; Muller, J. M.; Wernecke, K. D.; Baumann, G.; Roots, I.; Stangl, K. (2001) Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. Atherosclerosis 154, 651-658
58. Morin, I.; Devlin, A. M.; Leclerc, D.; Sabbaghian, N.; Halsted, C. H.; Finnell, R.; Rozen, R. (2003) Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol. Genet. Metab. 79, 197-200
59. Moscow, J. A.; Gong, M. K.; He, R.; Sgagias, M. K.; Dixon, K. H.; Anzick, S. L.; Meltzer, P. S.; Cowan, K. H. (1995) Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 55, 3790-3794
60. Prassad, P. D.; Ramamoorthy, S.; Leibach, F. H.; Ganapathy, V. (1995) Molecular cloning of the human placental folate transporter. Biochem. Biophys. Res. Commun. 206, 681-687
61. Pullarkat, S. T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y. P.; Ingles, S. A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S.; Lenz, H. J. (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70
62. Rady, P. L.; Szucs, S.; Matalon, R. K.; Grady, J.; Hudnall, S. D.; Kellner, L. H.; Nitowsky, H. Genetic polymorphism (G80A) of reduced folate carrier gene in ethnic populations. (2001) Mol. Genet. Metab. 73, 285-286
63. Roberts, S. J.; Chung, K. -N.; Nachmanoff, K.; Elwood, P. C. (1997) Tissue-specific promoters of the alpha human folate receptor gene yield transcripts with divergent 5′ leader sequences and different translational efficiencies. Biochem. J. 326, 439-447
64. Rothem, L.; Ifergan, I.; Kaufman, Y.; Priest, D. G.; Jansen, G.; Assaraf, Y. G. (2002) Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem. J. 367, 741-50
65. Sadlish, H.; Williams, F. M.; Flintoff, W. F. (2002) Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem. J. 364, 777-786
66. Schuetz, J. D.; Matherly, L. H.; Westin, E. H.; Goldman, I. D. (1988) Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate resistant murine L1210 leukemia cell line. J. Biol. Chem. 263, 9840-9847
67. Schwahn, B.; Rozen, R. (2001) Polymorphisms in the methylenetetrahydrofolate reductase gene. Clinical consequences. Am. J. Pharmacogenomics 1, 189-201
68. Shaw, G. M.; Lammer, E. J.; Zhu, H.; Baker, M. W.; Neri, E.; Finnell, R. H. (2002) Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am. J. Med. Genet. 108, 1-6
69. Shaw, G. M.; Zhu, H.; Lammer, E. J.; Yang, W.; Finnell, R. H. (2003) Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am. J. Epidemiol. 158, 747-752
70. Sierra, E. E.; Brigle, K. E.; Spinella, M. J.; Goldman, I. D. (1997) pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells - further evidence for a third route mediated at low PH. Biochem. Pharmacol. 53: 223-231
71. Sirotnak, F. M.; Moccio, D. M.; Kelleher, L. E.; Goutas, L. J. (1981) Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res. 41, 4442-4452
72. Sirotnak, F. M.; Tolner, B. (1999) Carrier-mediated membrane transport of folates in mammalian cells. Ann. Rev. Nutr. 19, 91-122
73. Stokstad, E. L. R. (1990) Historical perspective on key advances in the biochemistry and physiology of folates. In: Folic Acid Metabolism in Health and Disease, (Picciano MF, Stokstad ELR, Gregory JF, Eds) New York: Wiley-Liss, pp. 1-21
74. Taub, J. W.; Matherly, L. H.; Rots, M. G.; van Zantwijk, C. H.; Kaspers, G. J. L.; Ravindranath, Y. (2002) Polymorphisms in methylene tetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 16, 764-765
75. Toffoli, G.; Veronesi, A.; Boiocchi, M.; Crivellari, D. (2000) MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate and fluorouracil (CMF). Ann. Oncol. 11, 373-375
76. Tolner, B.; Roy, K.; Sirotnak, F. M. (1998). Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5′ end heterogeneity. Gene 211, 331-341
77. Turner, F. B.; Andreassi II J. L.; Ferguson, J. Titus, S.; Tse, A.; Taylor, S. M.; Moran, R. G. (1999) Tissue-specific expression of functional isoforms of mouse folypoly-gamma-glutamate synthetase: a basis for targeting folate antimetabolites. Cancer Res. 59, 6074-6079
78. Turner, F. B.; Taylor, S. M.; Moran, R. G. (2000) Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J. Biol. Chem. 275, 35960-35968
79. Ueland, P. M.; Hustad, S.; Schneede, J.; Refsum, H.; Vollset, S. E. (2001) Biological and clinical implications of the MTHFR C677T polymphorism. Trends in Pharmcol. Sci. 22, 195-201
80. Ulrich, C. M.; Yasui, Y.; Storb, R.; Schubert, M. M.; Wagner, J. L.; Bigler, J.; Ariail, K. S.; Keener, C. L.; Li, S.; Liu, H.; Farin, F. M.; Potter, J. D. (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylene tetrahydrofolate reductase C677T polymorphism. Blood 98, 231-234
81. van der Put, N. M.; Gabreels, F.; Stevens, E. M.; Smeitink, J. A.; Trijbels, F. J.; Eskes, T. K.; van den Heuvel, L. P.; Blom, H. J. (1998) A second common mutation in the methylene tetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62, 1044-1051
82. van Ede, A. E.; Laan, R. F.; Blom, H. J.; Huizinga, T. W.; Haagsma, C. J.; Giesendorf, B. A.; de Boo, T. M.; van de Putte, L. B. (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44, 2525-2530
83. Wang, Y.; Zhao, R.; Russell, R. G.; Goldman, I. D. (2001) Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim. Biophys. Acta 1513, 49-54
84. Weisberg, I.; Tran, P.; Christensen, B.; Sibani, S.; Rozen, R. (1998) A second genetic polymorphism in methylene tetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64, 169-172
85. Whetstine, J.R.; Matherly, L.H. (2001) The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a CAMP-response element/AP-1-like element. Basis for tissue-specific gene expression. J. Biol. Chem. 276, 6350-6358
86. Whetstine, J. R.; Gifford, A. J.; Witt, T.; Liu, X. Y.; Flatley, R. M.; Norris, M.; Haber, M.; Taub, J. W.; Ravindranath, Y.; Matherly, L. H. (2001). Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res. 7, 3416-3422
87. Whetstine, J. R.; Flatley, R. M.; Matherly, L. H. (2002a) The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: Identification of seven non-coding exons and characterization of a novel promoter. Biochem. J. 367, 629-640
88. Whetstine, J. R.; Witt, T. L.; Matherly, L.H. (2002b) The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a 61 base pair polymorphism. J. Biol. Chem. 277, 43873-44380
89. Williams, F. M. R.; Flintoff, W. F. (1995) Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem. 270, 2987-2992
90. Wilson, A.; Platt, R.; Wu, Q.; Leclerc, D.; Christensen, B.; Yang, H.; Gravel, R. A.; Rozen, R. (1999) A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol. Genet. Metab. 67, 317-323
91. Winkelmayer, W. C.; Eberle, C.; Sunder-Plassmann, G.; Fodinger, M. (2003) Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney Int. 63, 2280-2285
92. Wong, S. C.; McQuade, R.; Proefke, S. A.; Matherly, L. H. (1997) Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity. Biochem. Pharmacol. 53, 199-206
93. Wong, S. C.; Proefke, S. A.; Bhushan, A.; Matherly, L. H. (1995) Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. (1995) J. Biol. Chem. 270, 17468-17475
94. Wong, S. C.; Zhang, L.; Witt, T. L.; Proefke, S. A.; Bhushan, A.; Matherly, L. H. (1999) Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J. Biol. Chem. 274, 10388-10394
95. Yang, R.; Sowers, R.; Mazza, B.; Healey, J. H.; Huvos, A.; Grier, H.; Bernstein, M.; Beardsley, G. P.; Krailo, M. D.; Devidas, M.; Bertino, J. R.; Meyers, P. A.; Gorlick, R. (2003) Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin. Cancer Res. 9, 837-844
96. Zeng, H.; Chen, Z. S.; Belinsky, M. G.; Rea, P. A.; Kruh, G. D. (2001) Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res. 61, 7225-7232
97. Zeng, H.; Liu, G.; Rea, P. A.; Kruh, G. D. (2000) Transport of aphipathic anions by human multidrug resistance protein 3. Cancer Res. 60, 4779-4784
98. Zhang, L.; Wong, S, C.; Matherly, L. H. (1998a). Structure and organization of the human reduced folate carrier gene. Biochim. Biophys. Acta 1442, 389-393
99. Zhang, L.; Wong, S. C.; Matherly, L. H. (1998b). Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons. Biochem. J. 332, 773-780
100. Zhang, L.; Taub, J. W.; Williamson, M.; Wong, S. C.; Hukku, B.; Pullen, J.; Ravindranath, Y.; Matherly, L. H. (1998c). Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin. Cancer Res. 4, 2169-2177
101. Zhao, R.; Assaraf, Y. G.; Goldman, I. D. (1998) A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol Chem. 373, 7873-7879
102. Zhao, R.; Gao, F.; Wang, Y.; Diaz, G. A.; Gelb, B. D.; Goldman, I. D. (2001a) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J. Biol. Chem. 276, 1114-1118
103. Zhao, R.; Russell R. G.; Wang, Y.; Liu, L.; Gao F.; Kneitz, B.; Edelman, W.; Goldman, I. D. (2001b) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J. Biol. Chem. 276, 10224-10228